Next 10 |
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. H...
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Mad...
2024-04-23 06:30:13 ET Bank of America Securities analyst issues UNDERPERFORM recommendation for MDGL on April 22, 2024 06:15AM ET. MDGL was trading at $213.49 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations ar...
2024-04-22 11:18:39 ET Summary The Simplify Propel Opportunities ETF (SURI) is a healthcare-based fund that provides exposure to global fixed income and equity markets in the healthcare sector. SURI has a since-inception return of -13%, but its recent performance has shown potenti...
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-13 03:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-10 10:15:00 ET Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly. Mid-cap biotechs Madrigal Pharmaceuticals (NASDAQ: MDGL) and Ax...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. H...
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Mad...
2024-04-23 06:30:13 ET Bank of America Securities analyst issues UNDERPERFORM recommendation for MDGL on April 22, 2024 06:15AM ET. MDGL was trading at $213.49 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations ar...